NCT06021067 is a Phase 1, PHASE2 clinical trial of Death mesenchymal stem cell in Radiation Lung Injury, sponsored by Sichuan University.

Who is sponsoring NCT06021067?

NCT06021067 is sponsored by Sichuan University.

What drugs are being tested in NCT06021067?

Interventions in NCT06021067: Death mesenchymal stem cell.

What condition does NCT06021067 study?

NCT06021067 studies Radiation Lung Injury.

Is NCT06021067 still recruiting?

NCT06021067 is currently status unknown. Last updated 1 September 2023.

Last reviewed 2023-09-01 · How we verify

NCT06021067

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dead Mesenchymal Stem Cells for Radiation Lung Injury

Status unknown Phase 1, PHASE2 Last updated 1 September 2023

What this trial tests

Phase 1, PHASE2 trial testing Death mesenchymal stem cell in Radiation Lung Injury in 15 participants. Status unknown.

Timeline

10 September 2023

Primary endpoint
10 September 2024

30 September 2024

Quick facts

Lead sponsor	Sichuan University
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	10 September 2023
Primary completion	10 September 2024
Estimated completion	30 September 2024
Sites	1 location across China

Drugs / interventions tested

Death mesenchymal stem cell — full drug profile →

Conditions studied

Radiation Lung Injury — all drugs for Radiation Lung Injury →

Sponsor

Sichuan University

Who can join

Adults 18 to 75, any sex, with Radiation Lung Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this single center, single arm and prospective study is to explore the safety and efficacy of hDMSCs in the treatment of radiation pneumonitis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Mesenchymal stem cells in injury repair of vital organs: from mechanism to clinical application.
Bao L, Wang Z, Li L, Tang S, et al · · 2025 · cited 1× · PMID 40686745 · DOI 10.62347/ygxa7976

Verify or expand the search:

Other Sichuan University trials

Trials by the same sponsor.

NCT07501169 — Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lun · Phase 2 · not yet recruiting
NCT07362732 — Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection · EARLY_PHASE1 · not yet recruiting
NCT07374250 — Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma · Phase 2 · not yet recruiting
NCT07332663 — Exploratory Study on the Treatment of Relapsed and Refractory B-cell Malignant Tumors With WGb-0301 Injection · EARLY_PHASE1 · not yet recruiting
NCT07258147 — Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06021067 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sichuan University
Last refreshed: 1 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06021067.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing